Psilocybin-Assisted Integration Therapy

Education, preparation, and integration—no drug provision

NuvoMind provides psychotherapy that helps you prepare for a legal psilocybin experience and integrate insights afterward, so meaningful moments translate into everyday change. Psilocybin is not FDA‑approved; NuvoMind does not prescribe, dispense, or administer psilocybin in California clinics, and we do not assist in sourcing controlled substances.

How integration helps

We work on intentions and safety before, and meaning‑making and behavior change after, a legally obtained experience. Tools draw from cognitive and acceptance‑based therapies, mindfulness, and motivational interviewing—tailored to your goals.

Study highlights (education‑only)

• Davis 2021 (JAMA Psych, MDD): ~71% response and ~54% remission at 4 weeks with psilocybin‑assisted therapy.
• Goodwin 2022 (NEJM, TRD): single supported 25 mg dose improved MADRS at 3 weeks vs 1 mg; safety events reported.
• COMPASS release 2022: ~30% remission at week 3 with 25 mg vs ~8% in low‑dose control (company summary of NEJM data).
• Carhart‑Harris 2021 (NEJM): primary endpoint not significantly different vs escitalopram; several secondary measures (incl. remission) favored psilocybin.
• Griffiths 2016 (cancer): substantial and sustained reductions in anxiety/depression vs control.
• Ross 2016 (cancer): immediate, sustained improvements in anxiety/depression and quality of life.
• Gukasyan 2022 (12‑mo follow‑up MDD): response ~75% and remission ~58% at 12 months among participants from the parent study.
• Raison 2023 (JAMA): 25 mg psilocybin with support improved depression scores in MDD.
• Frontiers 2024 review: among 5 MDD RCTs, ~60% reported beneficial primary outcomes; most showed anxiolytic benefits.
• BMJ 2024 meta‑analysis: significant benefit of psilocybin vs placebo on depressive symptoms.

What we provide / do not provide

Provide: education, preparation, risk awareness, post‑experience integration, and coordination with your existing care (with consent).
Do not provide: prescribing/dispensing/administering psilocybin or assistance with sourcing; no claims of cure or guaranteed outcomes.

References (educational, not exhaustive)

1. Davis AK et al. JAMA Psychiatry. 2021.
2. Goodwin GM et al. NEJM. 2022.
3. Carhart‑Harris R et al. NEJM. 2021.
4. Griffiths RR et al. J Psychopharmacol. 2016.
5. Ross S et al. J Psychopharmacol. 2016.
6. Gukasyan N et al. J Psychopharmacol. 2022.
7. Raison CL et al. JAMA. 2023.
8. Li LJ et al. Frontiers in Psychiatry. 2024.
9. Metaxa AM et al. BMJ. 2024.
10. COMPASS Pathways press summary (NEJM Goodwin 2022).

This page is informational and not a substitute for medical advice. Outcomes vary.